Ph-Positive Leukemia: No Longer a Death Sentence?

TOPLINE: A combination of targeted treatment and immunotherapy has revolutionized Philadelphia chromosome–positive acute lymphoblastic leukemia management, achieving long-term survival rates of 75%-80% without systemic chemotherapy or transplantation. METHODOLOGY:  Researchers initiated a treatment protocol in 2000 using tyrosine kinase inhibitors plus glucocorticoids for induction without systemic chemotherapy…